Real-world data suggests Sputnik V vaccine is 97.6% effective, says RDIF
Data comes from 3.8 million Russians vaccinated with COVID-19 vaccine
20th April 2021
Latest news
Breakthrough designation granted for Amgen’s bemarituzumab
Amgen gained access to bemarituzumab as part of its acquisition of Five Prime Therapeutics
20th April 2021
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer
Decision is based on results from the Phase II DESTINY-Breast01 trial
20th April 2021
NICE’s five-year strategy sets a ‘positive vision for the future’
Pharma and diagnostic sectors respond to organisation’s latest guideline recommendations
20th April 2021
NICE unveils new strategy to improve patient access to innovative treatments
Five-year strategy will seek to transform key elements of organisation's approach to latest treatments
19th April 2021
Phico Therapeutics gains £13.1m grant to advance antibacterial therapy
SASPject PT3.9 is designed for the treatment of hospital infections caused by Pseudomonas aeruginosa
19th April 2021
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
Ublituximab significantly reduced the annualised relapse rate in patients with relapsing forms of multiple sclerosis
19th April 2021
New advice on COVID-19 vaccination for pregnant women in UK
JCVI advises pregnant women in the UK be offered COVID-19 vaccination at the same time as the rest of the population
19th April 2021
EC approves new Sarclisa indication
Sarclisa has been approved in combination with a standard of care regimen for relapsed multiple myeloma
19th April 2021
New subcutaneous formulation of Tysabri approved in UK
Multiple sclerosis treatment can now be administered subcutaneously or intravenously
16th April 2021
EMA begins review of GSK/Vir’s COVID-19 antibody
The review will include an interim analysis of efficacy and safety data from the Phase III COMET-ICE trial
16th April 2021
Roche’s SMA treatment Evrysdi demonstrates continued improvements in infants
Drug continuously improved motor function and survival in babies after 24 months of treatment
16th April 2021
NICE recommends Alexion’s PNH treatment Ultomiris
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
16th April 2021
Alchemab completes £60m Series A funding to advance novel antibody platform
The funding will be used to advance Alchemab’s novel platform to identify disease-modifying antibody therapeutics
15th April 2021
Magic mushroom compound psilocybin shows ‘promise’ in depression
Researchers from Imperial College London say compound is at least as effective as a leading antidepressant in a therapeutic setting
15th April 2021
